The fight against type 2 diabetes just reached a groundbreaking milestone. Last week, the U.S. Food and Drug Administration ...

The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.

This could start to bring down the cost of brand-name competitors—here's who may get to use it, and one major difference from ...

Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...

The move intensifies an ongoing legal battle, as Novo Nordisk joins its major competitor Eli Lilly in opposing a recent initiative by the Outsourcing Facilities Association to include liraglutide in ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

The US Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), ...

The U.S. Food and Drug Administration has approved the first generic version of Victoza (liraglutide injection), ...

By comparison, the FDA-approved drug liraglutide only resulted in just under 6% weight loss after 26 weeks, the researchers ...

The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a ...

The generic liraglutide includes a Boxed Warning to advise ... "Today's approval underscores the FDA's continued commitment to advancing patient access to safe, effective, and high-quality generic ...

According to the Company, the generic product will launch immediately. The Food and Drug Administration (FDA) has approved Liraglutide Injection, the first generic version of Victoza ®.